迟发性运动障碍患者中舒必利治疗范围的评估。
Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia.
作者信息
Roos R A, Van der Velde E A, Buruma O J, de Wolff F A
出版信息
J Neurol Neurosurg Psychiatry. 1986 Sep;49(9):1055-8. doi: 10.1136/jnnp.49.9.1055.
Ten patients with tardive dyskinesia were treated with tiapride at an increasing dosage to establish the dose-concentration relationship and the dose-effect relationship. The effect was scored with the Abnormal Involuntary Movement Scale (AIMS) and the Doppler-radar method. The intra individual dosage-serum concentration correlation coefficients varied from 0.86 to 0.99 and the slopes of the individual regression lines varied from 0.16 to 0.58. All patients showed a diminution of their involuntary movements during the treatment period. A negative correlation coefficient was found between the dosage of tiapride and the AIMS; range -0.22 till -0.93, mean: -0.65 +/- 0.23 (SD). The Doppler-radar method results were inconclusive. No side-effects were observed.
对10例迟发性运动障碍患者使用硫必利进行治疗，剂量逐渐增加，以建立剂量-浓度关系和剂量-效应关系。采用异常不自主运动量表（AIMS）和多普勒雷达法对疗效进行评分。个体内剂量-血清浓度相关系数在0.86至0.99之间，个体回归线斜率在0.16至0.58之间。所有患者在治疗期间不自主运动均减少。硫必利剂量与AIMS之间存在负相关系数；范围为-0.22至-0.93，平均值：-0.65±0.23（标准差）。多普勒雷达法的结果尚无定论。未观察到副作用。
Zotero 插件